On Mar. 6, 2020, Cocrystal Pharma announced it had initiated its Coronavirus program. Cocrystal previously entered into a license agreement with Kansas State University Research Foundation (KSURF) to further develop certain proprietary broad-spectrum antiviral compounds for humans to treat Norovirus and Coronavirus infections.

Cocrystal intended to pursue research and development of theses antiviral compounds, including preclinical and clinical development. This license advanced the Company’s antiviral programs significantly by providing potent compounds for further development.